Daniel Berney
Overview
Explore the profile of Daniel Berney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
863
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patrikidou A, Oing C, Markellos C, Heidenreich A, Leao R, Nicolai N, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39915218
The 2021 updated International Germ Cell Cancer Collaborative Group classification for seminomatous germ cell tumours confirmed and refined the original classification, introducing the notion that lactate dehydrogenase (LDH) elevation above...
2.
Wagner T, Toft B, Lauritsen J, Bandak M, Christensen I, Engvad B, et al.
Eur J Cancer
. 2024 Mar;
202:114025.
PMID: 38531266
Background: Approximately 30% of patients with clinical stage I non-seminoma (CSI-NS) relapse. Current risk stratification is based on lymphovascular invasion (LVI) alone. The extent to which additional tumor characteristics can...
3.
Wagner T, Toft B, Lauritsen J, Bandak M, Christensen I, Engvad B, et al.
J Clin Oncol
. 2023 Sep;
42(1):81-89.
PMID: 37683134
Purpose: Approximately 20% of patients with clinical stage I seminoma relapse. Tumor size and rete testis invasion have been identified as risk factors for relapse. However, the level of evidence...
4.
Al-Hammouri T, Almeida-Magana R, Lawrence R, Duffy T, White L, Burke E, et al.
BMC Cancer
. 2023 Jun;
23(1):581.
PMID: 37353740
Background: Treatment decisions in prostate cancer (PCa) rely on disease stratification between localised and metastatic stages, but current imaging staging technologies are not sensitive to micro-metastatic disease. Circulating tumour cells...
5.
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Nardo D, et al.
Eur Urol
. 2023 May;
84(3):289-301.
PMID: 37183161
Context: Each year the European Association of Urology (EAU) produce a document based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular cancer (TC). Objective: To...
6.
Davies C, Guo T, Burke E, Stankiewicz E, Xu L, Mao X, et al.
Front Oncol
. 2023 Feb;
12:1060864.
PMID: 36727071
Background: Docetaxel improves overall survival (OS) in castration-resistant prostate cancer (PCa) (CRPC) and metastatic hormone-sensitive PCa (mHSPC). However, not all patients respond due to inherent and/or acquired resistance. There remains...
7.
Forster D, Marzouk S, Chakraborti I, Berney D, Wolfe K, Liyanage S
BJR Case Rep
. 2023 Jan;
8(6):20220072.
PMID: 36632556
Testicular adrenal rest tumours (TART) are found in patients with congenital adrenal hyperplasia (CAH) with the severity of testicular infiltration linearly related to the degree of enzymatic defect and subsequent...
8.
Rubin M, Amin M, Comperat E, Gill A, Hartman A, Menon S, et al.
Eur Urol
. 2022 Oct;
83(1):e16-e17.
PMID: 36202688
No abstract available.
9.
Guo T, Wang Y, Jia J, Mao X, Stankiewicz E, Scandura G, et al.
Front Cell Dev Biol
. 2021 Jan;
8:602493.
PMID: 33490068
Castration-resistant prostate cancer (CRPC) is the major cause of death from prostate cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-invasive liquid biopsies could improve outcomes....
10.